RTP Mobile Logo
Head & Neck Cancer Update, Issue 1, 2013
Released April 2013

Featuring interviews with Drs Marshall Posner, Barbara Burtness, Robert Haddad and Ezra EW Cohen. (Audio Content)

CE Disclosures and Faculty Information


    Approximately 53,640 new cases of head and neck cancer are estimated to occur in the United States during 2013, and more than 11,000 patients will die from the disease. The most common sites of this condition, which is predominantly of squamous cell origin, include the oral cavity, pharynx and larynx. Accounting for 3% of all new cancers, head and neck cancers represent a group of tumors largely arising from identifiable and preventable environmental carcinogens, including smoking and alcohol use.

    Treatment for patients with head and neck cancer is complex and requires a multidisciplinary team of individuals with expertise in the special care needs of these patients. The site and extent of disease and pathologic findings dictate the appropriate surgical approach, radiation field, dose and fractionation and indications for chemotherapy and/or biologic therapy. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists and radiation oncologists must be well informed of these advances. To bridge the gap between research and patient care, Head and Neck Cancer Update features one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists physicians with the formulation of up-to-date clinical management strategies.

    • Counsel patients with HPV-positive squamous cell carcinoma of the head and neck (SCCHN) about the contribution of the virus to the etiology and prognosis of their disease, and use this information and other relevant clinical factors to guide treatment decision-making.
    • Identify patients with SCCHN who may be appropriate candidates for induction chemotherapy prior to chemoradiation therapy, and counsel these individuals accordingly regarding the risks and benefits of this approach.
    • Formulate an evidence-based approach to the use of chemoradiation therapy alone or in combination with EGFR monoclonal antibody therapy for patients with locally advanced SCCHN.
    • Develop evidence-based multimodality treatment approaches for patients with recurrent or metastatic SCCHN whose disease has progressed following platinum-based treatment.
    • Evaluate novel surgical approaches (eg, transoral robotic surgery) for patients with oropharyngeal SCC previously considered to be unresectable, and refer appropriate cases for consultation with an experienced thoracic surgeon.
    • Recall the efficacy and tolerability of promising investigational VEGFR and EGFR inhibitors being evaluated in SCCHN.
    • Counsel appropriately selected patients about participation in ongoing clinical trials.
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component. To receive credit, the participant listen to the audio MP3s.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
    FACULTYDr Haddad had no real or apparent conflicts of interest to report. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr PosnerAdvisory Committee: Novartis Pharmaceuticals Corporation; Data and Safety Monitoring Board: Eisai Inc; Paid Research: Lilly USA LLC. Dr BurtnessAdvisory Committee: Bristol-Myers Squibb Company; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation. Dr CohenAdvisory Committee: Lilly USA LLC; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company.
    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewersfor Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc and Lilly USA LLC.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

Acknowledge and close

Listen to audio:
Head & Neck Cancer Update, Issue 1, 2013
Released April 2013

Featuring interviews with Drs Marshall Posner, Barbara Burtness, Robert Haddad and Ezra EW Cohen. (Audio Content)

Read print: